TABLE 5

Prevalence of baseline polymorphisms in NS3 and/or NS5A in GT3-infected patients

HCV GTNS3 polymorphismaNS5A polymorphisma
TypebPrevalence (%)cTypePrevalence (%)
3aAny NS315.9 (96/605)Any NS5A21.4 (130/607)
F43L0.2 (1/605)S24A2.0 (12/607)
T54(A/S)0.5 (3/605)M28V1.2 (7/607)
V55I0.2 (1/605)A30(L/M/R/S/T/V)5.9 (36/607)
Y56F0.2 (1/605)A30K6.4 (39/607)
Q80K0.2 (1/605)P58(A/R/S/T/Y)3.6 (22/607)
A166S9.1 (55/605)E92(D/G)0.3 (2/607)
A166T5.0 (30/605)Y93H/F4.9 (30/607)
Q168K1.0 (6/605)
Q168R0.7 (4/605)
3bAny NS3(0/6)Any NS5A100 (6/6)
K30M16.7 (1/6)
V31M100 (6/6)
3iAny NS3(0/2)Any NS5A(0/2)
All GT3Any NS315.7 (96/613)Any NS5A22.1 (136/615)
  • a Polymorphisms relative to subtype-specific reference sequences at a 15% detection threshold at amino acid position 36, 43, 54, 55, 56, 80, 155, 156, 166 or 168 in NS3 or position 24, 28, 30, 31, 32, 58, 92, or 93 in NS5A.

  • b “Any” indicates the total number of patients with any polymorphism within each target.

  • c Values in parentheses are the number of patients with the polymorphism/total number of patients in the group with available sequence.